Penson, R. T., Arend, R. C., Secord, A. A., Herraez, A. C., Herzog, T. J., Ledermann, J. A., … Monk, B. J. (2022). Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Penson, Richard T., Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, et al. “Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Penson RT, Arend RC, Secord AA, Herraez AC, Herzog TJ, Ledermann JA, et al. Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Penson, Richard T., et al. “Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Penson RT, Arend RC, Secord AA, Herraez AC, Herzog TJ, Ledermann JA, Moore KN, Shapira-Frommer R, Tewari KS, Minei TR, Harats D, Shmueli SF, Monk BJ. Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). JOURNAL OF CLINICAL ONCOLOGY. 2022.